Johnson & Johnson vaccine effective against delta COVID-19 variant

By

Johnson & Johnson has announced that data from eight months study have shown that the company’s COVID-19 vaccine is effective against the highly contagious Delta variant.

In a news release, the company said that data from the study “demonstrated its single-shot COVID-19 vaccine generated strong, persistent activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants.”

In addition, the data showed that the durability of the immune response lasted through at least eight months, the length of time evaluated to date.

- Advertisement -

“We believe that our vaccine offers durable protection against COVID-19 and elicits neutralizing activity against the Delta variant,” said the Vice-Chairman of the Executive Committee and Chief Scientific Officer at Johnson & Johnson, Paul Stoffels.

He observed that the result of the study adds to the robust body of clinical data supporting the company’s single-shot vaccine’s ability to protect against multiple variants of concern.

Paul Stoffels of Johnson & Johnson

Adding to this, the Global Head, Janssen Research and Development, Johnson & Johnson, Dr Mathai Mammen, said, “We observe a persistent and particularly robust, durable cellular immune response.”

She added, “With each new dataset, we build on our solid foundation of evidence that our single-shot COVID-19 vaccine plays a critical role in ending the pandemic, which continues to evolve and pose new challenges to global health.”

The Janssen COVID-19 vaccine works well against the Delta variant that now dominates new infections in South Africa, the head of the country’s Medical Research Council, Glenda Gray, said on Friday, July 2.

- Advertisement -

“All the data that we see indicate good immediate and sustained immune response against Delta, and we see surprising durability in the immune response for the single-dose J&J right up to eight months,” she said at a news conference.

The delta variant of the COVID-19 is now rife in Europe and has spread worldwide since initially being identified in India.

With the vaccine showing about 85% efficacy, it is believed that it could prevent serious illness and hospitalization.

READ ALSO: Johnson And Johnson Vaccine: FDA Finds The Single-Shot Jab Safe

The World Health Organisation (WHO) reports that, globally, as of 11:00 a.m Central European Summer Time (CEST), 2 July 2021, there have been 182,101,209 confirmed cases of COVID-19, including 3,950,876 deaths.

The organisation also reports that, as of 1 July 2021, 2,950,104,812 vaccine doses have been administered.

COVID-19 has affected 220 countries and territories, with the United States of America, India and Brazil being the three countries with higher cases.

Support
Share This Article
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *